Published on : Dec 15, 2017
ALBANY, New York, December 15, 2017: The instance of neurodegenerative diseases has been increasing especially due to the rising toll of geriatric population. This is expected to fuel the market for neurodegenerative diseases and garner attention from various entities within medical sciences. The report by Rmoz titled ‘Frontier Pharma: Neurodegenerative Diseases - Protein Misfolding Targets and Neuromodulators Dominate the First-in-Class Pipeline and Lead the Way as Potential Disease-Modifying Therapies in AD and PD’ mainly analyses the market for neurodegenerative diseases in key areas such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Multiple Sclerosis (MS). The report offers succinct insights on the existing treatment algorithm for the diseases, and sheds light on the need to circumvent a route that offers better scope for treatment.
The currently functional therapies for AD and PD merely relieve the symptomatic suffering failing to entirely eliminate the disease. However, the domain of treatment for MD has been taking positive leaps through the development of effective therapies. The drugs such as GABA receptor modulators, cholinergic receptor agonists, and anti-amyloid protein agents are expected to drive market growth for Alzheimer’s market. For Parkinson’s disease, the market is anticipated to be fueled by adrenergic and adenosine antagonists, dopamine receptor agonists and reuptake inhibitors, and glutamate receptor modulators. Moreover, the etiological risk factors associated with AD, PD, and MD are required to be enunciated along with the processes implicated for these.
Get SAMPLE REPORT PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=1389106
The bane caused by neurodegenerative diseases is abysmal which has prompted medical researchers from across the globe to invest time, resources, and manpower towards finding effective therapies. The focused research and development (R&D) initiatives pertaining to the treatment of neurodegenerative disorders have propelled the growth of the market. Furthermore, aging population has been on a rise in recent times and the extremity of occurrence of AD and PD amongst them has further expanded the market. The high awareness quotient of contemporary researchers is amongst other reasons that drive the growth of the market foe neurodegenerative disorders.
The current treatment algorithm for neurodegenerative disease alleviates the symptoms of AD and PD but does not evict these diseases altogether. This owes to the fact that the neurodegenerative diseases are extremely adverse and expansive to be easily tamed. The chronic and virtually fatal nature of the disease hinders the growth of the market. The high levels of investment in R&D by the various pharmaceutical companies hasn’t rendered any significant results towards the treatment of neurodegenerative diseases. As a result, medical circles are skeptical of the current treatment mechanism for AD and PD which further obstructs the market.
Medical sciences have engaged in rigorous R&D to find succinct cure for neurodegenerative diseases which is expected to restore the faith of various groups of people towards the drugs and antidotes. Moreover, there are unmet needs for the treatment of AD and PD which is anticipated to provide an opportunity for the market to bid on newly developed drugs for the treatment of these diseases. The research in regards to SD has witnessed significantly effectual results which offers scope for the market to grow.
The major market players in the neurodegenerative market include UCB, Biogen Idec, Merck Serono, Boehringer Ingelheim, TEVA Pharmaceuticals Industries, Novartis, Pfizer, and GlaxoSmithKlineSanofi S.A. amongst others.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]